MRUS: Merus N.V. Common Shares Company Profile & Statistics

Merus N.V. Common Shares Profile

About

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Info & Links

CEO

Sven (Bill) Ante Lundberg

Headquarters

UPPSALALAAN 17
UTRECHT, P7 3584 CT, NETHERLANDS

Auditor

KPMG Accountants N.V.

Share holders

266

Employees

260

Merus N.V. Common Shares Statistics

Valuation Measures

Market Capitalization²

5.14B

Enterprise Value

4.70B

Enterprise Value/EBITDA(ttm)

-13.56

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

68.92

Price to Book(mrq)

6.33

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-442.87%

Profit Margin(ttm)

-835.86%

Return on Equity(ttm)

-35.99%

Return on Invested Capital(ttm)

-53.96%

Return on Assets(ttm)

-29.83%

Income Statement

Revenue(ttm)

56.23M

Revenue Per Share(ttm)

0.74

Gross Profit(ttm)

56.23M

EBITDA(ttm)³

-346.30M

Net Income Available to Common(ttm)

-385.52M

Diluted EPS(ttm)

-4.08

Share Statistics

Beta (5Y Monthly)

1.00

52-Week Change

35.69%

S&P 500 52-Week Change

17.44%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

75.63M

Dividend Yield

0.00%

Float⁴

66.05M

% Held by Insiders

4.57%

% Held by Institutions

96.14%

Balance Sheet

Total Cash(mrq)

710.22M

Total Cash Per Share(mrq)

9.39

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

8.39%

Quick Ratio(mrq)

5.86%

Book Value Per Share(mrq)

11.14

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.33

Free Cash Flow(ytd)

-165.95M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

MRUS

Merus N.V. Common Shares